Cancer vaccines have been utilized as a therapeutic modality to treat prostate cancer in clinical studies for several decades.
Recently with the approval of sipuleucel-T, vaccines have now been accepted as standard therapy for this disease. The androgen receptorhas long been recognized as a therapeutic target for the treatment of patients with locally advanced as well as metastatic disease. Recent preclinical studies described by Olson et al. have focused on the androgen receptor as a target for prostate cancer immunotherapy. They have developed and tested a DNA vaccine targeting the ligand-binding domain of the androgen receptor and have demonstrated in animal studies the ability to elicit T-cell responses towards the vaccine that have resulted in both antitumor activity as well as increased survival in the animal models described.
Written by:
Arlen PM. Are you the author?
Precision Biologics, Inc., 9700 Great Seneca Hwy, Suite 321, Rockville, MD 20850, USA.
Reference: Expert Rev Vaccines. 2013 Mar;12(3):249-51.
doi: 10.1586/erv.13.17
PubMed Abstract
PMID: 23496664
